GlassScriptPhysician profile
Maria E Crippen
NPI 1588963342
$1,891.38
in general payments reported to CMS, 2019-2025
24 companies · $367 in 2025
The $367 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.92 · 2022: $593 · 2023: $598 · 2024: $321 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.38 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $293.53 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $281.84 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $142.18 | 2023-2025 | Myfembree |
| Pfizer INC. | $124.71 | 2022-2024 | |
| Abbvie INC. | $113.31 | 2022-2023 | |
| Organon LLC | $110.45 | 2022-2025 | Nexplanon |
| Aspira Women'S Health INC | $101.38 | 2022-2023 | Ova1 |
| Mayne Pharma Commercial LLC | $99.62 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.55 | 2022-2025 | |
| Myriad Women'S Health, INC. | $77.98 | 2023 | Myrisk |
| Myovant Sciences INC. | $61.97 | 2022 | |
| Biogen, INC. | $58.28 | 2024 | Zurzuvae |
| Millicent US INC | $55.69 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Daiichi Sankyo INC. | $54.15 | 2022-2023 | Injectafer |
| Mycovia Pharmaceuticals, INC. | $40.22 | 2022-2023 | Vivjoa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $37.37 | 2022-2024 | Myosure Tissue Removal Device, Novasure |
| Lilly USA, LLC | $36.74 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $22.59 | 2024 | Lynparza, Keytruda |
| Scynexis, INC. | $18.09 | 2022 | |
| Ethicon US, LLC | $17.99 | 2022 | |
| Therapeuticsmd, INC. | $17.84 | 2022 | |
| Avion Pharmaceuticals | $15.30 | 2022 | |
| Agile Therapeutics, INC. | $14.68 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Crippen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.